Salarius Pharmaceuticals Statistics
Total Valuation
SLRX has a market cap or net worth of $2.25 million. The enterprise value is $2.04 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SLRX has 509,643 shares outstanding.
| Current Share Class | 509,643 |
| Shares Outstanding | 509,643 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 2.54% |
| Float | 508,927 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.61
| Current Ratio | 0.61 |
| Quick Ratio | 0.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -660.37% and return on invested capital (ROIC) is -459.32%.
| Return on Equity (ROE) | -660.37% |
| Return on Assets (ROA) | -143.52% |
| Return on Invested Capital (ROIC) | -459.32% |
| Return on Capital Employed (ROCE) | 684.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.55M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.77% in the last 52 weeks. The beta is 0.50, so SLRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -82.77% |
| 50-Day Moving Average | 7.68 |
| 200-Day Moving Average | 15.68 |
| Relative Strength Index (RSI) | 34.32 |
| Average Volume (20 Days) | 344,688 |
Short Selling Information
The latest short interest is 123,799, so 24.29% of the outstanding shares have been sold short.
| Short Interest | 123,799 |
| Short Previous Month | 1.19M |
| Short % of Shares Out | 24.29% |
| Short % of Float | 24.33% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.68M |
| Pretax Income | -6.46M |
| Net Income | -5.10M |
| EBITDA | -5.68M |
| EBIT | -5.68M |
| Earnings Per Share (EPS) | n/a |
Full Income StatementBalance Sheet
The company has $794,886 in cash and n/a in debt, giving a net cash position of $794,886 or $1.56 per share.
| Cash & Cash Equivalents | 794,886 |
| Total Debt | n/a |
| Net Cash | 794,886 |
| Net Cash Per Share | $1.56 |
| Equity (Book Value) | -829,724 |
| Book Value Per Share | n/a |
| Working Capital | -862,924 |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.14M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.14M |
| FCF Per Share | -$8.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
